Search results
- AVTX-002 is a fully human monoclonal antibody, directed against human LIGHT (L ymphotoxin-like, exhibits I nducible expression, and competes with Herpes Virus G lycoprotein D for H erpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes).
People also ask
What does avtx-002 stand for?
What is Avalo avtx-002?
What is avtx-002 antibody?
Does avtx-002 reduce light levels?
AVTX-002 is in Phase 2 development for non-eosinophilic asthma (NEA), inflammatory bowel diseases (IBD) and COVID-19 acute respiratory distress syndrome (ARDS). Targeting LIGHT LIGHT is a newly recognized cytokine with inflammatory actions encoded by the TNFSF14 gene.
Jun 26, 2023 · AVTX-002 is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus...
Jan 6, 2022 · AVTX-002 for the treatment of non-eosinophilic asthma (NEA): NEA is a significant subtype of asthma with a poor prognosis that encompasses approximately half of asthma patients.
May 18, 2022 · The primary endpoint is the proportion of subjects who experience an asthma-related event. At baseline, subjects will be randomized to receive either AVTX-002 or placebo once monthly. NEA. Asthma is a chronic disease of the lungs characterized by airway inflammation causing swelling and excess mucous production.
Jun 26, 2023 · About AVTX-002 (quisovalimab) AVTX-002 is a fully human monoclonal antibody (mAb), directed against human LIGHT ( L ymphotoxin-like, exhibits I nducible expression, and competes with Herpes...
Jan 17, 2023 · AVTX-002, Avalo’s lead development asset, is a fully human monoclonal antibody (mAb), directed against human LIGHT ( L ymphotoxin-like, exhibits I nducible expression, and competes with Herpes Virus G lycoprotein D for H erpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes).
Jun 26, 2023 · AVTX-002 is a revolutionary Fully Human Monoclonal Antibody (mAb) that targets LIGHT, a key regulator of the immune system. Dysregulation of this network is an underlying mechanism of autoimmune and inflammatory diseases, making therapeutic intervention of LIGHT an attractive approach.
